ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, inhibition of BCR/ABL by imatinib treatment increased both TXNIP protein and mRNA levels in CML cell lines (K562, KCL22, and KU812) and primary CML cells from patients (CML#1 and CML#2) (Fig. 1E, F).